Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban vs Warfarin in High Risk Antiphospholipid Syndrome
NCT02157272Phase 3Terminated
- Sponsor
- Università di Padova
- Start
- Dec 2014
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of rivaroxaban in antiphospholipid syndrome (APS), sponsored by Università di Padova. Started Dec 2014; status: terminated.
02
Drugs
rivaroxaban
03
Conditions
antiphospholipid syndrome (APS)
Beyond the preview
Go deeper on NCT02157272.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02157272.